Welcome to our dedicated page for Jocom Holdings SEC filings (Ticker: JOCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jocom Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jocom Holdings's regulatory disclosures and financial reporting.
Jocom Holdings Corp. notified the SEC that it is unable to file its Annual Report on Form 10-K for the period ended December 31, 2025. The company says it needs additional time to compile and analyze supporting documentation and to permit its independent registered public accounting firm to complete its audit.
Jocom Holdings Corp. (JOCM) filed its Q3 2025 10‑Q reporting a net loss and a going concern warning. The company posted a net loss of $126,819 for the nine months ended September 30, 2025, versus net profit of $37,218 a year ago, driven by general and administrative expenses of $213,914 (up from $80,165) and $0 revenue (vs. $18,000). Other income was $87,095.
Operating cash outflow was $479,644, partly offset by $500,000 net cash from financing after $800,000 of unregistered common stock sales at $0.10 per share, with a $300,000 subscription receivable outstanding. Cash ended at $22,987. The company recorded $348,000 in deposits as earnest money toward acquiring Yijun (Shanghai) Biotechnology Co. Ltd., stated as expected to complete by Q2 2026. 65,680,500 shares were outstanding as of September 30, 2025, and stockholders’ equity improved to $306,769.
Management disclosed material weaknesses in internal controls and stated that recurring losses, accumulated deficit, and negative operating cash flows raise substantial doubt about continuing as a going concern.